A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

NCT06079736 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped PGN-EDO51 development terminated by Sponsor

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: PGN-EDO51

Sponsor

PepGen Inc